X4 Pharmaceuticals
X4 Pharmaceuticals is a Boston-based biopharmaceutical company that develops and commercializes oral CXCR4 antagonists for rare immune disorders, with its approved product XOLREMDI (mavorixafor) serving WHIM syndrome patients in the US and EU and an ongoing Phase 3 program in chronic neutropenia.
- Company typePublic
- Founded2014
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What X4 Pharmaceuticals does
X4 Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company founded in 2014 that develops oral small-molecule therapeutics targeting the CXCR4/CXCL12 pathway for rare diseases of the immune system. Its lead asset, mavorixafor (marketed as XOLREMDI), is an oral, once-daily CXCR4 receptor antagonist that regulates mobilization of white blood cells from bone marrow into circulation; it is the first drug ever approved in the United States (April 2024) and the European Union (April 2026) for the treatment of WHIM syndrome in patients 12 years and older. The company is advancing mavorixafor through the pivotal global Phase 3 4WARD trial in chronic neutropenia, a larger label opportunity, with enrollment of 176 patients targeted for completion by Q3 2026 and potential 2028 approval.
The business operates a hybrid commercial model: in the United States, X4 deploys its own field force of Medical Science Liaisons, Patient Diagnostic Liaisons, and a nurse educator and supports patients through the X4Connect program, while international commercialization is executed via specialist partners (Norgine for Europe, Australia, and New Zealand; taiba rare for the MENA region). Revenue is generated from XOLREMDI net product sales in the US, licensing and milestone payments from partners, and royalties; FY2025 total revenue was approximately $35.1 million ($6.5 million product plus $28.6 million license), with $233.7 million of cash at the end of Q1 2026 providing runway through 2028. The company is publicly traded on Nasdaq under XFOR and has executed a substantial leadership refresh in 2025 oriented toward pipeline execution and value-creating transactions.
X4 Pharmaceuticals firmographics
Firmographics- Name
- X4 Pharmaceuticals
- Legal name
- X4 Pharmaceuticals, Inc.
- Website
- https://x4pharma.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- X4 Pharmaceuticals is a Boston-based biopharmaceutical company that develops and commercializes oral CXCR4 antagonists for rare immune disorders, with its approved product XOLREMDI (mavorixafor) serving WHIM syndrome patients in the US and EU and an ongoing Phase 3 program in chronic neutropenia.
- Ownership category
- akta.pro rank
X4 Pharmaceuticals industry classification
Industry- Product category
- Rare Disease Biopharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
- akta.pro secondary industries
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
Keywords
Where X4 Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
X4 Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- XOLREMDI Product Sales: Net product sales of XOLREMDI (mavorixafor) in the United States following FDA approval in April 2024. The company deployed a commercial team including field force of Medical Science Liaisons, Patient Diagnostic Liaisons, and nurse educator to drive sales.
- Licensing and Milestone Revenue: License agreement with Norgine worth up to €226 million in milestones plus escalating double-digit royalties for European commercialization of XOLREMDI. Includes one-time license revenue recognized from prior agreements.
- Full Year 2025 Revenue: Full year 2025 revenue of $6.5 million in net product sales and $28.6 million in license revenue, totaling approximately $35.1 million.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
X4 Pharmaceuticals product offering
Product offeringCore offering
X4 Pharmaceuticals develops and commercializes XOLREMDI® (mavorixafor), an oral, once-daily CXCR4 receptor antagonist approved in the US (April 2024) and EU (April 2026) as the first treatment for WHIM syndrome in patients aged 12 and older. The company also advances mavorixafor through a global pivotal Phase 3 4WARD clinical trial for chronic neutropenia, with a 176-patient enrollment target and potential 2028 commercial approval. X4 supports patients and providers through its X4Connect program offering insurance support and copay assistance for eligible US patients.
Product overview
X4 Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system. The company's primary product is XOLREMDI® (mavorixafor), an FDA-approved oral therapy for WHIM syndrome launched in the U.S. in May 2024 and approved in the EU in April 2026, with commercialization led by partner Norgine in Europe. The company is advancing mavorixafor through the pivotal global Phase 3 4WARD trial for chronic neutropenic disorders, with patient enrollment targeted for completion by Q3 2026. X4 supports patients through its X4Connect program providing treatment support, insurance assistance, and copay programs, and maintains an Expanded Access Program for eligible WHIM syndrome patients outside the U.S.
Differentiator
Problem solved
Functional benefit
Brands
- XOLREMDI: FDA-approved oral, once-daily therapy for patients 12 years and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes
- X4Connect
Products and services
- XOLREMDI® (mavorixafor) FDA- and EU-approved oral, once-daily CXCR4 receptor antagonist therapy for patients 12 years and older with WHIM syndrome, designed to increase the number of circulating mature neutrophils and lymphocytes. Sold in the US through X4's direct commercial field force and supported ex-US through licensing partners Norgine (EU, Australia, New Zealand) and taiba rare (MENA).
- Mavorixafor (investigational chronic neutropenia program) Investigational development of mavorixafor as an oral, once-daily therapy for chronic neutropenic disorders, targeting the same CXCR4/CXCL12 pathway to mobilize white blood cells. Designed as an oral alternative or complement to injectable G-CSF, the only approved therapy for severe chronic neutropenia for the past 30 years. Target US market of approximately 15,000 symptomatic chronic neutropenia patients representing a $400-600 million peak revenue opportunity.
Quantifiable outcome
- Approximately 40% reduction in total infection score vs placebo in Phase 3 WHIM trial
- +4 more outcomes
Companies that use X4 Pharmaceuticals
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
X4 Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
X4 Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- NorginecoreLicensing and supply agreement with Norgine, a leading European specialist pharmaceutical company, for commercialization of mavorixafor (XOLREMDI) in the European Union, Australia, and New Zealand. Under the agreement, Norgine leads commercialization and assumes responsibility for all market access activities, while X4 manufactures and supplies the drug. The agreement is worth up to €226 million in milestones plus escalating double-digit royalties. The European Commission granted marketing authorization in April 2026.
- taiba rarecoreExclusive agreement with taiba rare for distribution and commercialization of XOLREMDI in Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt, following any regulatory approvals in the territories. taiba rare has specialty and orphan drug marketing, sales, and distribution expertise in the MENA region.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
X4 Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Amicus Therapeutics: Commercial-stage rare disease biotech focused on oral therapies for ultra-rare genetic disorders (Fabry, Pompe). Directly comparable business model to X4: small-molecule, specialty commercial team, similar patient population scale. CCO Mark Baldry previously led global commercial at Amicus.
- BioMarin Pharmaceutical: Mid-cap rare disease biopharma with multiple approved specialty therapies and ongoing pipeline in inherited conditions. Comparable structure: orphan-drug commercial model, regulatory exclusivity leverage, partnership-based international expansion.
- Ultragenyx Pharmaceutical: Clinical-to-commercial rare disease biotech developing and commercializing therapies for ultra-rare genetic diseases. Similar size, patient population profile, and reliance on orphan drug exclusivity economics.
- Rhythm Pharmaceuticals: Ultra-rare disease biotech with FDA-approved setmelanotide (Imcivree) for rare genetic obesity disorders. Comparable profile: small addressable population, oral/specialty therapy, MSL-driven commercial model. Board member Murray Stewart previously served as CMO of Rhythm.
- Swedish Orphan Biovitrum (Sobi): European specialty biopharma focused on rare diseases, recently completed $1.7B acquisition of CTI BioPharma (X4 Executive Chair Adam Craig's prior company). Directly comparable as Norgine's competitor in European orphan drug distribution and rare-disease commercialization.
- CTI BioPharma: Small-cap hematology/rare disease biotech acquired by Sobi for $1.7B in 2023. Multiple members of X4's current leadership (Craig, Volpone, Kirske) previously held senior roles at CTI, providing a directly comparable operating blueprint for orphan drug commercialization and exit.
Broad incumbents
- Alexion (AstraZeneca Rare Disease): Established rare disease franchise within AstraZeneca, focused on complement-mediated and metabolic rare disorders. Comparable commercial model in ultra-rare disease; broader portfolio and larger scale than X4.
- Vertex Pharmaceuticals: Larger rare-disease specialist with multiple approved therapies for serious specialty conditions. Comparable in commercial sophistication and orphan-drug focus, though operates at materially greater scale.
- Genzyme (Sanofi): Sanofi's rare disease franchise pioneered the orphan drug commercial model. Highly relevant precedent: founder Paula Ragan led strategic partnering at Genzyme Rare Disease, and Gary Bridger held senior R&D roles there. Sanofi's Genzyme unit established the playbook X4 is executing.
Regional players
- Recordati Rare Diseases: European-headquartered specialty pharma with significant rare disease focus. Comparable to Norgine as a potential distribution partner for X4 in non-US geographies; operates an established rare disease commercial infrastructure in Europe.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
X4 Pharmaceuticals social profiles
Digital presenceX4 Pharmaceuticals compliance and trust
Trust signalCompliance2 records
X4 Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
X4 Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles14 records
X4 Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds13 records
Investors23 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
X4 Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about X4 Pharmaceuticals
What does X4 Pharmaceuticals do?
X4 Pharmaceuticals develops and commercializes XOLREMDI® (mavorixafor), an oral, once-daily CXCR4 receptor antagonist approved in the US (April 2024) and EU (April 2026) as the first treatment for WHIM syndrome in patients aged 12 and older. The company also advances mavorixafor through a global pivotal Phase 3 4WARD clinical trial for chronic neutropenia, with a 176-patient enrollment target and potential 2028 commercial approval. X4 supports patients and providers through its X4Connect program offering insurance support and copay assistance for eligible US patients.
Is X4 Pharmaceuticals a public or private company?
X4 Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was X4 Pharmaceuticals founded?
X4 Pharmaceuticals was founded in 2014. It employs 51 to 100 people.
Where is X4 Pharmaceuticals based?
X4 Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.
How does X4 Pharmaceuticals make money?
Three revenue lines are on record. XOLREMDI Product Sales are the primary driver. The others are licensing and Milestone Revenue and full Year 2025 Revenue.
Who are X4 Pharmaceuticals's main competitors?
Direct peers on record are Amicus Therapeutics, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, Swedish Orphan Biovitrum (Sobi) and CTI BioPharma. Broad incumbents are Alexion (AstraZeneca Rare Disease), Vertex Pharmaceuticals and Genzyme (Sanofi). Recordati Rare Diseases is listed as a regional player.
Does X4 Pharmaceuticals have an API?
No public API is recorded for X4 Pharmaceuticals.
What industry is X4 Pharmaceuticals in?
X4 Pharmaceuticals's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its SIC code is 2834.